Nuvectis Pharma, Inc. Reports Second Quarter 2022 Financial Results and Business Highlights
NXP800 Phase 1a Dose-Escalation Study Progressing as Planned, Commencement of Phase 1b Expansion Study Expected in Q1 2023NXP800 IND Cleared by the U.S. FDA, U.S. and U.K. Sites Now Participating in... | August 5, 2022
Source: marketscreener.com